Actively Recruiting

Early Phase 1
Age: 18Years - 65Years
All Genders
Healthy Volunteers
NCT05656105

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

Led by University of Alabama at Birmingham · Updated on 2025-12-11

60

Participants Needed

1

Research Sites

237 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This clinical imaging study will use the small molecule translocator protein (TSPO) ligand, Fluorodeoxyglucose(18F)-labeled DPA-714, to visualize and quantify neuroinflammation in individuals with post-acute sequelae of SARS-CoV-2 (PASC) . The brain uptake of DPA-714 will be contrasted with healthy subjects.

CONDITIONS

Official Title

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

Who Can Participate

Age: 18Years - 65Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 65 years
  • Healthy volunteer or clinical diagnosis of post-acute sequelae of SARS-CoV-2 (PASC)
  • High or mixed affinity binder for TSPO ligands based on genotyping for SNP rs6971
  • PASC participants must have had SARS-CoV-2 infection and neurological symptoms for at least four weeks before enrollment
  • Healthy controls must have no neurological symptoms
Not Eligible

You will not qualify if you...

  • Contraindication to MRI
  • Pregnancy
  • Lactation
  • Unable to participate in imaging due to severe medical condition
  • Chronic infectious diseases like HIV or hepatitis C
  • Viral or bacterial illness needing medical care or antibiotics within 1 month before study
  • Diagnosis of cancer, including leukemia
  • Blood or clotting disorders
  • Autoimmune diseases except Multiple Sclerosis
  • Positive pregnancy test on day of procedure or within 48 hours before DPA-714 administration
  • Enrollment in clinical trials using experimental therapies
  • Taking experimental therapies currently
  • Low affinity binder for TSPO ligands based on genotyping for SNP rs6971
  • History of moderate or severe traumatic brain injury
  • History of whiplash injury
  • History of inflammatory bowel disease (IBD); irritable bowel syndrome (IBS) allowed if no inflammation
  • Abnormal blood test results including elevated rheumatoid factor, anti-nuclear antibody, ESR, hsCRP, abnormal CBC, thyroid hormone levels, fasting glucose above 100 mg/dL, or blood chemistry indicating organ damage
  • Use of illicit substances within past 6 months
  • Diagnosis of Type I or Type II diabetes
  • Healthy controls must not regularly use anti-inflammatory, analgesic (except aspirin), or sleep medications

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

UAB

Birmingham, Alabama, United States, 35249

Actively Recruiting

Loading map...

Research Team

A

April Riddle

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here